Premenstrual Syndrome Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Premenstrual Syndrome Treatments Market is segmented by Drug Type (Analgesics, Antidepressant, Oral Contraceptive, Ovarian Suppression Agents, Gonadotropin-Releasing Hormone (GnRH) Analogues, Selective Serotonin Reuptake Inhibitors (SSRIs), and Others), Product Type ( Prescription and OTC), Distribution Channel ( Hospital Pharmacies, Drug Store and Retail Pharmacies, E-commerce), Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

Premenstrual Syndrome Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Premenstrual Syndrome Treatment Industry Overview

The premenstrual syndrome treatment market is moderately competitive, with several players across the globe. Few big firms currently dominate the market in terms of market share. The companies are raising investment and funding for the development of therapies for the treatment of Premenstrual Syndrome. Bayer AG, Eli Lilly and Company, GlaxoSmithKline Plc, Pfizer Inc., H. Lundbeck A/S are the leading market players with significant market share.

Premenstrual Syndrome Treatment Market Leaders

  1. Eli Lilly and Company

  2. GlaxoSmithKline Plc

  3. H. Lundbeck A/S

  4. MetP Pharma AG

  5. Bayer AG

  6. *Disclaimer: Major Players sorted in no particular order
Picture1 sybdrome.png